Collectively, our study characterized the functional and transcriptomic profiles of MHC class I-restricted cytotoxic CD4+ TCR-Ts, and revealed the multifaceted killing mechanisms of this T cell subset, suggesting that they could serve as potent cancer immunotherapies. Here, CD4 is linked to cancer.